TSOI Stock ,Therapeutic Solutions International (TSOI) announced the appointment of Mrs. Famela Ramos as Chief Executive Officer of Res Nova Bio, Inc. The announcement also included the creation of an advisory board to steer the direction of the Company. The company was founded by a spinoff of Therapeutic Solutions International with the aim of commercializing Stem Vacs V in the field of breast cancer.
StemVacs can be described as an “off the shelf” cancer immunotherapy that instructs an immune system that can destroy blood vessels that supply cancer. Contrary to the initial generation of cancer anti-angiogenesis treatment that relied on placental cells and which had been granted FDA approval for clinical studies, StemVacs-V utilizes an established pluripotent stem cells as an invariably stable and reliable source of the immunegen.
Therapeutic Solutions International Returns vs. S&P
| 1 YEAR | 5 YEAR | 5 YEAR ANNUALIZED | SINCE IPO | |
|---|---|---|---|---|
| TSOI | -79.06% | -41.67% | -10.20% | -97% |
| S&P | -8.93% | +57.20% | +9.47% | +209% |
Assets
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Net Cash | $0.11M | +45.2% |
| Accounts Receivable | $0.04M | +97.2% |
| Inventory | 0.044943 | -26.8% |
Liabilities
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Long Term Debt | $0.01M | -56.5% |
| Short Term Debt | $1.08M | -1.4% |
Ratios
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Return On Assets | -150.4% | -44.7% |
| Return On Invested Capital | 156.0% | +36.0% |
Cash Flow
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Free Cash Flow | -$0.20M | +35.6% |
| Operating Free Cash Flow | -$0.20M | +61.6% |
Valuation
QUARTERLYANNUAL
| Q4 2021 | Q1 2022 | Q2 2022 | Q3 2022 | YOY CHANGE | |
|---|---|---|---|---|---|
| Price to Earnings | – | – | – | – | – |
| Price to Book | -60.42 | -52.08 | 21.88 | 15.11 | – |
| Price to Sales | 452.14 | 285.25 | 237.10 | 140.80 | -85.5% |
| Price to Tangible Book Value | -53.37 | -46.01 | -52.56 | -30.90 | -62.3% |
| Price to Free Cash Flow TTM | – | – | – | – | – |
| Enterprise Value to EBITDA | -73.70 | -116.93 | -55.65 | -55.58 | -66.9% |
| Free Cash Flow Yield | – | – | – | – | – |
| Return on Equity | – | -724.3% | -820.3% | -1153.6% | – |
| Total Debt | $1.10M | $1.12M | $1.10M | $1.09M | -3.0% |
